Federico Monaca, Senior Clinical Research Fellow at The Christie NHS Foundation Trust, shared a post on LinkedIn:
“Pleased to share our review in the Journal of Thoracic Oncology.
A key message is that the challenge is no longer only whether ADCs are active in relapsed SCLC, but how to position them alongside DLL3-directed T-cell engagers in clinical practice.
ADCs may achieve higher early response rates, while T-cell engagers may offer more durable benefit in a subset of patients.
The real unanswered questions are patient selection, sequencing, target modulation, and potential cross-resistance, especially with so many ADCs sharing TOP1-inhibitor payloads.
Grateful to my co-authors for this collaboration.”
Title: Antibody–Drug Conjugates in Small-Cell Lung Cancer
Authors: Federico Monaca, Igor Gomez-Randulfe, Javier Torres-Jiménez, Muskan Agarwal, Stephen V. Liu, Luis Paz-Ares, Raffaele Califano
Read the full article here.
Other articles featuring Federico Monaca on OncoDaily.
